Biotin and high-sensitivity cardiac troponin T assay

Biochemia Medica

Volumn 28, Issue 3, 2018, Pages

  Schrapp, Aurélien ^a   Fraissinet, François ^a   Hervouet, Charles ^a   Girot, Hélène ^a   Brunel, Valéry ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

Biotin; Multiple sclerosis; Preanalytical phase; Troponin T

Indexed keywords

BIOLOGICAL MARKER; BIOTIN; STREPTAVIDIN; TROPONIN T;

ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CONCENTRATION LOSS; CONTROLLED STUDY; HEART INFARCTION; HUMAN; INCUBATION TIME; LIMIT OF DETECTION; MULTIPLE SCLEROSIS; PRE-ANALYTICAL PHASE; PREDICTIVE VALUE; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SERODIAGNOSIS; SPIKE; TURNAROUND TIME; BLOOD; CARDIAC MUSCLE; METABOLISM; PROCEDURES; TIME FACTOR;

BIOTIN; BLOOD CHEMICAL ANALYSIS; HUMANS; LIMIT OF DETECTION; MYOCARDIUM; TIME FACTORS; TROPONIN T;

EID: 85055517160     PISSN: 13300962     EISSN: None     Source Type: Journal    
DOI: 10.11613/BM.2018.030901     Document Type: Article

References (9)

1. Chenevier-Gobeaux C, Meune C, Blanc M-C, Cynober L, Jaffray P, Lefevre G. Analytical evaluation of a high-sensitivity troponin T assay and its clinical assessment in acute coronary syndrome. Ann Clin Biochem. 2011;48:452-8. https://doi.org/10.1258/acb.2011.011019
2. Franeková J, Bláha M, Bělohoubek J, Kotrbatá M, Sečník P, Kubíček Z, et al. A clinical and laboratory approach used to elucidate discordant results of high-sensitivity troponin T and troponin I. Clin Chim Acta. 2015;446:128-31. https://doi.org/10.1016/j.cca.2015.03.046
3. Trambas C, Lu Z, Yen T, Sikaris K. Characterization of the scope and magnitude of biotin interference in susceptible Roche Elecsys competitive and sandwich immunoassays. Ann Clin Biochem. 2018;55:205-15. https://doi. org/10.1177/0004563217701777
4. Sedel F, Papeix C, Bellanger A, Touitou V, Lebrun-Frenay C, Galanaud D, et al. High doses of biotin in chronic progressive multiple sclerosis: a pilot study. Mult Scler Relat Disord. 2015;4:159-69. https://doi.org/10.1016/j.msard.2015.01.005
5. Trambas C, Lu Z, Yen T, Sikaris K. Depletion of biotin using streptavidin-coated microparticles: a validated solution to the problem of biotin interference in streptavidin-biotin immunoassays. Ann Clin Biochem. 2018;55:216-26. https://doi.org/10.1177/0004563217707783
6. Piketty M-L, Prie D, Sedel F, Bernard D, Hercend C, Chanson P, et al. High-dose biotin therapy leading to false biochemical endocrine profiles: validation of a simple method to overcome biotin interference. Clin Chem Lab Med. 2017;55:817-25. https://doi.org/10.1515/cclm-2016-1183
7. Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:267-315. https://doi.org/10.1093/eurheartj/ehv320
8. Annette-Reisch M, Soubiran P, Szymanowicz A, and members of the subgroup 1 pre-analytics. [Guidelines for the pre-examination processing and transport of medical laboratory samples]. Ann Biol Clin (Paris). 2010;68:111-29. (In French)
9. Grimsey P, Frey N, Bendig G, Zitzler J, Lorenz O, Kasapic D, et al. Population pharmacokinetics of exogenous biotin and the relationship between biotin serum levels and in vitro immunoassay interference. Int J Pharmacokinet. 2017;2:247-56. https://doi.org/10.4155/ipk-2017-0013